Cuba has independently developed five COVID-19 vaccines (including Abdala and Soberana 02, both approved for emergency use) with a plan to vaccinate 70 percent of its population by August.

But they now face a syringe shortage and challenges from the United States’ trade embargo.

Today on the show, Thursday host Allen Ruff discusses these and other updates from Cuba with Bob Schwartz, executive director of Global Health Partners.

Cover image: “Aplicación de vacuna Abdala” by Cubadebate on YouTube, licensed under CC BY 3.0